Europe Medical Collagen Market is expected to reach US$ 255.72 million by 2028

PRESS RELEASE BY The Insight Partners 01 Sep 2021

Share this press on

The bovine segment by source is estimated to lead the market growth during the forecast period.

According to The Insight Partners market research study of “Europe Medical Collagen Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Source, Product, Application and Country.” The Europe medical collagen market is expected to reach US$ 255.72 million in 2028 from US$ 175.11 million in 2021; it is estimated to grow at a CAGR of 5.6% from 2021 to 2028. The report highlights trends prevailing in the Europe medical collagen market and the factors driving market along with those that act as hindrances. 

A medical product with collagen as a part is being studied to treat several conditions. Owing to its clinical and consumer acceptance, it is widely used as a medical material. Collagen-based medical products such as bioprosthetic heart valves, arterial replacements, sutures used in surgical procedures, and wound dressings have been widely adopted. Thus, several research studies are being conducted to develop new collagen-based medical products. For instance, in 2020, MPM Medical initiated its CoMatryx Surgical Bovine Collagen Study. CoMatryx surgical collagen powder is a soft tissue repair product made of 100% Type-I Bovine collagen. Furthermore, research is being conducted to discover new sources of collagen for medical biomaterials. For instance, the study ‘Tilapia (Oreochromis aureus) Collagen for Medical Biomaterials’ was published in 2018. The researchers studied the potentials of tilapia skin as an alternative source of collagen for its application in the medical biomaterial. Thus, the increasing research activities for collagen-based medical products are likely to drive the growth of the market during the forecast period. Also, various players operating in the medical collagen market are developing and launching new products to expand their geographic reach and capacity to cater to many customers. Thus, constant advancements in medical collagen products and approvals regulatory bodies are factors further driving the growth of the medical collagen market.

Europe has been witnessing a growing number of COVID-19 cases since its outbreak. However, the health and wellness market in Europe is observing steady growth due to the outbreak of COVID-19. Collagen peptides are among the products gaining excellent popularity during the pandemic. Europeans are looking at different and natural ways for staying healthy and enhancing their immune system. So, there is increased interest in how collagen peptides can enhance vitamins and health supplements and help people with their health and wellness amid the pandemic.  Also, due to social distancing practices, consumers are experiencing changes to their daily routines involving grooming and skincare. This has led to an increased demand for nutricosmetics that can be used at home. This is likely to drive the growth of skincare collagen products. Hence, COVID-19 has had a positive impact on the Europe medical collagen market.

The Europe medical collagen market, by source, is segmented into bovine, porcine, and others. The Europe medical collagen market, by product, is segmented into gelatine, hydrolysed collagen, native collagen, and others. Based on application, the Europe medical collagen market has been segmented into haemostats, vascular grafts, tissue scaffolds, cartilage repair, wound care, bone grafts, diagnostics, and other. Geographically, the Europe medical collagen market can be sub-segmented into UK, Germany, France, Italy, Spain and Rest of Europe.

DSM, Collagen Solutions Plc, Innocoll Pharmaceuticals, ENCOLL Corp, CollPlant Biotechnology, GELITA AG, Collagen Matrix, Inc., Integra Life Sciences Corporation, SYMATESE and Croda International plc are among the leading companies operating in the Europe medical collagen market.

Contact Us
Phone: +1-646-491-9876
Email Id: 

Download Free PDF Brochure